Health
Warning issued for diabetes drug
NEWS IN BRIEF — Posted Jan. 30, 2006
GlaxoSmithKline, in conjunction with the Food and Drug Administration, is warning physicians that rosiglitazone (Avandia) has, in a small number of patients, been linked to the onset or worsening of macular edema. A majority of the patients who developed this reaction already had peripheral edema, and, for many, the situation was resolved by reducing the dose or discontinuing the drug.
The label already advises physicians to use caution with this drug in patients who retain water, and the company plans to add information about macular edema in the future.
This condition tends to occur in conjunction with diabetic retinopathy and can lead to blurred vision and decreased color sensitivity.
The drug was approved for use in the United States in May, 1999. More than 5 million people with type 2 diabetes have taken it.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/01/30/hlbf0130.htm.












